<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30180856</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5.</ArticleTitle><Pagination><StartPage>249</StartPage><MedlinePgn>249</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">249</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-018-1610-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Enteroviral cardiomyopathy is a life-threatening disease, and detection of enterovirus (EV) RNA in the initial endomyocardial biopsy is associated with adverse prognosis and increased mortality. Some patients with EV infection may spontaneously eliminate the virus and recover, whereas those with virus persistence deteriorate and progress to heart failure. Interferon-beta (IFN-&#x3b2;) therapy eliminates the virus, resulting in increased survival of treated patients. CCR5 is expressed on antigen-presenting cells (both macrophages and dendritic cells) and immune effector cells (T-lymphocytes with memory/effector phenotype and natural killer cells). Its 32-bp deletion (CCR5del32) is the most frequent human coding sequence mutation. This study addresses the correlation of CCR5 polymorphism to the clinical course of EV infection and the necessity for IFN-&#x3b2; treatment.</AbstractText><AbstractText Label="METHODS">We examined 97 consecutive patients with chronic/inflammatory cardiomyopathy and biopsy-proven EV infection and reliable information on clinical outcomes by CCr5 genotyping. These data were evaluated in relation to virus persistence in follow-up biopsies and survival rates over a 15-year period.</AbstractText><AbstractText Label="RESULTS">Genotyping revealed a strong correlation between the CCR5del32 genotype and spontaneous virus clearance with improved outcomes. All patients with CCR5del32 eliminated EV spontaneously and none of them died within the observed period. In the group of untreated CCR5 wildtype patients, 33% died (Kaplan-Meier log-rank p&#x2009;=&#x2009;0.010). However, CCR5 wildtype individuals treated with IFN-&#x3b2; are more likely to survive than without therapy (Kaplan-Meier log-rank p&#x2009;=&#x2009;0.004) in identical proportions to individuals with the CCR5del32 genotype.</AbstractText><AbstractText Label="CONCLUSIONS">These data suggest that CCR5 genotyping is a novel predictive genetic marker for the clinical course of human EV cardiomyopathies. Hereby clinicians can identify those EV positive individuals who will eliminate the virus spontaneously based on CCR5 phenotype and those patients with CCR5 wildtype genotype who would be eligible for immediate antiviral IFN-&#x3b2; treatment to minimize irreversible cardiac damage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lassner</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0815-7013</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany. info@ikdt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegismund</LastName><ForeName>Christine S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0001-7909-1694</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hl</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-2476-0050</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Campus Virchow, Charit&#xe9;-University Hospital Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2046-8757</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroux</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biometry and Clinical Epidemiology, Campus Benjamin Franklin, Charit&#xe9;-University Hospital and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escher</LastName><ForeName>Felicitas</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0678-5681</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Campus Virchow, Charit&#xe9;-University Hospital Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultheiss</LastName><ForeName>Heinz-Peter</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0002-2185-3710</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>616 0315296</GrantID><Agency>Federal Ministry of Education and Research for the Small and Medium-sized Enterprises Innovative Program</Agency><Country>International</Country></Grant><Grant><GrantID>Sfb/Tr19</GrantID><Agency>Transregional Collaborative Research Centre (Inflammatory Cardiomyopathy-Molecular Pathogenesis and Therapy)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C584933">CCR5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019713" MajorTopicYN="N">Receptors, CCR5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCR5del32 genotype</Keyword><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Coxsackievirus</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Interferon-beta therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30180856</ArticleId><ArticleId IdType="pmc">PMC6123922</ArticleId><ArticleId IdType="doi">10.1186/s12967-018-1610-8</ArticleId><ArticleId IdType="pii">10.1186/s12967-018-1610-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE, Cunningham L, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582&#x2013;2589. doi: 10.1161/01.CIR.89.6.2582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.89.6.2582</ArticleId><ArticleId IdType="pubmed">8205668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LT. Myocarditis. N Engl J Med. 2009;360:1526&#x2013;1538. doi: 10.1056/NEJMra0800028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0800028</ArticleId><ArticleId IdType="pmc">PMC5814110</ArticleId><ArticleId IdType="pubmed">19357408</ArticleId></ArticleIdList></Reference><Reference><Citation>Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(2636&#x2013;48):2648a&#x2013;2648d.</Citation><ArticleIdList><ArticleId IdType="pubmed">23824828</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with &#x201c;idiopathic&#x201d; left ventricular dysfunction. Circulation. 2005;111:887&#x2013;893. doi: 10.1161/01.CIR.0000155616.07901.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000155616.07901.35</ArticleId><ArticleId IdType="pubmed">15699250</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112:1965&#x2013;1970. doi: 10.1161/CIRCULATIONAHA.105.548156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.548156</ArticleId><ArticleId IdType="pubmed">16172268</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus BM, Yanagawa B, Rezai N, Luo H, Taylor L, Zhang M, et al. Genetic determinants of coxsackievirus B3 pathogenesis. Ann N Y Acad Sci. 2002;975:169&#x2013;179. doi: 10.1111/j.1749-6632.2002.tb05950.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2002.tb05950.x</ArticleId><ArticleId IdType="pubmed">12538163</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev. 2013;18:761&#x2013;795. doi: 10.1007/s10741-012-9362-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-012-9362-7</ArticleId><ArticleId IdType="pubmed">23225133</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793&#x2013;2798. doi: 10.1161/01.CIR.0000072766.67150.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000072766.67150.51</ArticleId><ArticleId IdType="pubmed">12771005</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss H-P. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012;60:1295&#x2013;1296. doi: 10.1016/j.jacc.2012.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.06.026</ArticleId><ArticleId IdType="pubmed">23017536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss H-P, Piper C, Sowade O, Waagstein F, Kapp J-F, Wegscheider K, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-&#x3b2; treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016;105:763&#x2013;773. doi: 10.1007/s00392-016-0986-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-016-0986-9</ArticleId><ArticleId IdType="pubmed">27112783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66:1&#x2013;79. doi: 10.1124/pr.113.007724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.113.007724</ArticleId><ArticleId IdType="pmc">PMC3880466</ArticleId><ArticleId IdType="pubmed">24218476</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntinghe FLH, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol. 2009;20:1641&#x2013;1649. doi: 10.1681/ASN.2008040432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008040432</ArticleId><ArticleId IdType="pmc">PMC2709675</ArticleId><ArticleId IdType="pubmed">19389855</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;tter G, Nowak D, Mossner M, Ganepola S, M&#xfc;ssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692&#x2013;698. doi: 10.1056/NEJMoa0802905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802905</ArticleId><ArticleId IdType="pubmed">19213682</ArticleId></ArticleIdList></Reference><Reference><Citation>Allers K, H&#xfc;tter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5&#x394;32/&#x394;32 stem cell transplantation. Blood. 2011;117:2791&#x2013;2799. doi: 10.1182/blood-2010-09-309591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-09-309591</ArticleId><ArticleId IdType="pubmed">21148083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JK, Murphy PM. Chemokine control of West Nile virus infection. Exp Cell Res. 2011;317:569&#x2013;574. doi: 10.1016/j.yexcr.2011.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2011.01.009</ArticleId><ArticleId IdType="pmc">PMC3050559</ArticleId><ArticleId IdType="pubmed">21376172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015;5:15577. doi: 10.1038/srep15577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15577</ArticleId><ArticleId IdType="pmc">PMC4612538</ArticleId><ArticleId IdType="pubmed">26481100</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke. 2008;39:1972&#x2013;1978. doi: 10.1161/STROKEAHA.107.504381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.107.504381</ArticleId><ArticleId IdType="pubmed">18436884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassner D, Siegismund CS, Stehr J, Rohde M, Escher F, Tsch&#xf6;pe C, et al. Recent advances in molecular diagnostics and treatment of heart muscle diseases. J Anal Sci Methods Instrum. 2013;2013(June):98&#x2013;109.</Citation></Reference><Reference><Citation>Schultheiss H-P, K&#xfc;hl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32:2616&#x2013;2625. doi: 10.1093/eurheartj/ehr165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr165</ArticleId><ArticleId IdType="pubmed">21705357</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner A, Pauschinger M, Schwimmbeck PL, K&#xfc;hl U, Schultheiss HP. The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol. 2000;35:1778&#x2013;1784. doi: 10.1016/S0735-1097(00)00644-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(00)00644-6</ArticleId><ArticleId IdType="pubmed">10841224</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauschinger M, Phan MD, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889&#x2013;895. doi: 10.1161/01.CIR.99.7.889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.7.889</ArticleId><ArticleId IdType="pubmed">10027811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassner D, K&#xfc;hl U, Rohde M, Siegismund CS, Schultheiss H-P. CCR5del32 polymorphism is a protective factor in non-ischemic cardiomyopathy. Int J Cardiol. 2014;173:561&#x2013;562. doi: 10.1016/j.ijcard.2014.03.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.03.123</ArticleId><ArticleId IdType="pubmed">24721485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B&#xf6;hm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850&#x2013;1858. doi: 10.1093/eurheartj/ehv727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv727</ArticleId><ArticleId IdType="pubmed">26792875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossol M, Pierer M, Arnold S, Keysser G, Burkhardt H, Baerwald C, et al. Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R91. doi: 10.1186/ar2733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2733</ArticleId><ArticleId IdType="pmc">PMC2714147</ArticleId><ArticleId IdType="pubmed">19538721</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-&#x2206;32 HIV-resistance allele. Proc Natl Acad Sci USA. 2003;100:15276&#x2013;15279. doi: 10.1073/pnas.2435085100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2435085100</ArticleId><ArticleId IdType="pmc">PMC299980</ArticleId><ArticleId IdType="pubmed">14645720</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan&#x2013;Meier estimate. Int J Ayurveda Res. 2010;1(4):274&#x2013;278. doi: 10.4103/0974-7788.76794.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0974-7788.76794</ArticleId><ArticleId IdType="pmc">PMC3059453</ArticleId><ArticleId IdType="pubmed">21455458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewick V, Cheek L. Ball. Statistics review 12: survival analysis. J Crit Care. 2004;8(5):389&#x2013;394. doi: 10.1186/cc2955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc2955</ArticleId><ArticleId IdType="pmc">PMC1065034</ArticleId><ArticleId IdType="pubmed">15469602</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleijfer S, Bannink M, Gool AR, Kruit WHJ, Stoter G. Side effects of interferon-&#x3b1; therapy. Pharm World Sci. 2005;27:423&#x2013;431. doi: 10.1007/s11096-005-1319-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-005-1319-7</ArticleId><ArticleId IdType="pubmed">16341948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yajima T, Yasukawa H, Jeon E-S, Xiong D, Dorner A, Iwatate M, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation. 2006;114:2364&#x2013;2373. doi: 10.1161/CIRCULATIONAHA.106.642454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.642454</ArticleId><ArticleId IdType="pubmed">17101849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbea C, Makar KA, Pauschinger M, Pratt G, Bersola JLF, Varela J, et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem. 2010;285:23208&#x2013;23223. doi: 10.1074/jbc.M109.047464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.047464</ArticleId><ArticleId IdType="pmc">PMC2906314</ArticleId><ArticleId IdType="pubmed">20472559</ArticleId></ArticleIdList></Reference><Reference><Citation>Valaperti A, Nishii M, Liu Y, Naito K, Chan M, Zhang L, et al. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production. Circulation. 2013;128:1542&#x2013;1554. doi: 10.1161/CIRCULATIONAHA.113.002275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.002275</ArticleId><ArticleId IdType="pubmed">24030499</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkirane M, Jin D-Y, Chun RF, Koup RA, Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5{Delta}32. J Biol Chem. 1997;272:30603&#x2013;30606. doi: 10.1074/jbc.272.49.30603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.49.30603</ArticleId><ArticleId IdType="pubmed">9388191</ArticleId></ArticleIdList></Reference><Reference><Citation>Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950&#x2013;1959. doi: 10.1161/ATVBAHA.107.161224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.107.161224</ArticleId><ArticleId IdType="pubmed">18818421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schober A. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523&#x2013;1529. doi: 10.1161/01.CIR.0000028590.02477.6F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000028590.02477.6F</ArticleId><ArticleId IdType="pubmed">12234959</ArticleId></ArticleIdList></Reference><Reference><Citation>Candore G, Balistreri CR, Grimaldi MP, List&#xec; F, Vasto S, Caruso M, et al. Opposite role of pro-inflammatory alleles in acute myocardial infarction and longevity: results of studies performed in a Sicilian population. Ann N Y Acad Sci. 2006;1067:270&#x2013;275. doi: 10.1196/annals.1354.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1354.035</ArticleId><ArticleId IdType="pubmed">16803997</ArticleId></ArticleIdList></Reference><Reference><Citation>Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol. 2005;174:7341&#x2013;7351. doi: 10.4049/jimmunol.174.11.7341.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.7341</ArticleId><ArticleId IdType="pubmed">15905581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OM, Wang JM. Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J Biol Chem. 1997;272:11682&#x2013;11685. doi: 10.1074/jbc.272.18.11682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.18.11682</ArticleId><ArticleId IdType="pubmed">9115216</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T, The T, Cell-directed CC. Chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272:15036&#x2013;15042. doi: 10.1074/jbc.272.23.15036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.23.15036</ArticleId><ArticleId IdType="pubmed">9169480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirugo G, Predazzi IM, Bartlett J, Tacconelli A, Walther M, Williams SM. G6PD A-deficiency and severe malaria in The Gambia: heterozygote advantage and possible homozygote disadvantage. Am J Trop Med Hyg. 2014;90:856&#x2013;859. doi: 10.4269/ajtmh.13-0622.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.13-0622</ArticleId><ArticleId IdType="pmc">PMC4015578</ArticleId><ArticleId IdType="pubmed">24615128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>